The annual meeting of the Group was held on October 14, bringing together several representatives from the 15 hospital centers that are members of the Group, including those serving on its board of directors, scientific committee, and operations committee.
The meeting was an opportunity for the founding couple to highlight that 79 studies were selected by the scientific committee, with nearly 1,200 patients recruited in total. They also emphasized the important milestone of reaching 15 members in Quebec and Ontario, as well as surpassing 1,000 participants in the metastatic breast cancer registry.
Mr. Sirois also thanked several partners in attendance for their support, including Amgen, Astellas, AstraZeneca, BMS, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Knight, Novartis, Merck, Pfizer, Roche, Seagen, as well as Breast Cancer Canada, the Canadian Cancer Society, the Ministère de la santé et des services sociaux and Sardo.
Ms. McPeak highlighted the importance of the work accomplished together within the Consortium to help increase access to and participation in research that improves care across the province.
